Description: Stability and Storage:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Detection method:Colorimetric Sample type:Plasma, Serum Assay type:Quantitative Sensitivity:0.156 μg/ml Range:0.31-5 μg/mL Recovery:80-120% Background:Olokizumab (CDP6038), a humanized monoclonal antibody (mAb) specific for the interleukin-6 (IL-6) cytokine, is currently in development for the treatment of rheumatoid arthritis (RA). It targets the IL-6 cytokine rather than the receptor, and selectively blocks the final assembly of the signalling complex. In Phase I (healthy volunteers) and IIa (patients with RA on MTX) clinical trials, olokizumab was well tolerated after intravenous and subcutaneous delivery with a median plasma half-life of approximately 31?days, 76% bioavailability and no apparent antidrug antibody-mediated clearance. Olokizumab also markedly reduced free IL-6 levels and suppressed C-reactive protein (CRP) up to 12?weeks after single-dose subcutaneous administration in patients with RA. Shipping:2-8 ℃ Specifications:Olokizumab Note:For Research Use Only.